Editas Medicine, Inc.·4

Mar 4, 4:48 PM ET

Burkly Linda 4

4 · Editas Medicine, Inc. · Filed Mar 4, 2026

Insider Transaction Report

Form 4
Period: 2026-03-03
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Transactions
  • Sale

    Common Stock

    [F1][F2]
    2026-03-03$2.02/sh749$1,51368,028 total
Footnotes (2)
  • [F1]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.
  • [F2]This transaction was executed in multiple trades at prices ranging from $2.0041 to $2.0204. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected
Signature
/s/ Linda C. Burkly|2026-03-04

Documents

1 file
  • 4
    wk-form4_1772660918.xmlPrimary

    FORM 4